Clinical Trials

Multiple Myeloma

NCT00720785 2026-04-01

Natural Killer Cells and Bortezomib to Treat Cancer

LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03701321 2023-09-26

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Withdrawn

Multiple Myeloma

NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

57 enrolled 22 charts

Hematologic Diseases, Multiple Myeloma

NCT01109004 2021-12-09

BMT CTN 0702

Phase 3 Completed

758 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT01647165 2019-12-12

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01711528 2018-05-11

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

41 enrolled

Multiple Myeloma

NCT00006184 2017-10-20

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

20 enrolled 10 charts

Multiple Myeloma

NCT00522392 2015-06-26

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Phase 3 Terminated

48 enrolled 9 charts

Multiple Myeloma

NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 9 charts

Multiple Myeloma

NCT01078441 2015-01-12

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Phase 2 Terminated

2 enrolled 5 charts

Multiple Myeloma

NCT00082784 2014-12-23

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

93 enrolled

LymphoidPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00075881 2014-06-02

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

44 enrolled 8 charts

Multiple Myeloma

NCT00334932 2014-01-10

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Unknown

32 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00389701 2014-01-10

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Phase 2 Unknown

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Unknown

35 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00317811 2013-11-06

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

35 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00243035 2013-10-08

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Terminated

64 enrolled

Multiple Myeloma

NCT00316940 2013-09-20

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

36 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00054483 2013-05-16

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction